Treatment
Medication clinical trials
We’re tracking 7,138 recruiting studies that include Medication, each written for real people, not researchers, below.
Recruiting studies
- NCT06707012RecruitingPhase 4
Metformin plus antidepressants for depression in obesity
This trial tests whether adding metformin (a diabetes medicine) to usual antidepressant treatment can help improve depression in people who are overweight or obese. It is for adults age 18–44 who are newly diagnosed with depression and do not have diabetes.
Karachi, SindhAges 18–45 - NCT06709027Enrolling by invitation
Mobile health program for depression in older adults
This study is testing a smartphone-based health program designed for older adults with depression. The program aims to help you manage your mood and track changes in thinking and memory using a mobile app.
Fuzhou, FujianAges 60 years+ - NCT06712784Recruiting
Support for autistic patients during needle procedures
This trial tests a behavior support program to help autistic patients and their caregivers during needle-related hospital visits at Boston Medical Center. It aims to reduce challenging behaviors and make procedures easier for everyone involved.
Boston, MassachusettsAges 3 years+ - NCT06714240Recruiting
Extra protein to support muscle strength in ICU
This study tests whether giving extra protein through a feeding tube can help ICU patients maintain muscle strength. It may be an option for people who are expected to stay in the ICU for at least a week and need a breathing machine.
Hasselt, LimburgAges 18 years+ - NCT06364553Recruiting
Metal stent for swallowing problems from cancer
This study tests whether a metal tube (stent) placed in the esophagus can safely improve swallowing in people whose cancer blocks the food pipe and cannot be cured. It may help you eat and drink more comfortably.
Rotterdam, South HollandAges 18 years+ - NCT02393157RecruitingPhase 2
Obinutuzumab plus chemotherapy for certain CD20+ relapsed lymphomas
This Phase 2 study tests how well obinutuzumab (an antibody medicine) combined with chemotherapy works for people whose CD20-positive B-cell lymphoma has come back or didn’t respond to initial treatment. It may help by attacking lymphoma cells that carry the CD20 marker.
Valhalla, New YorkAges 3–31 - NCT03266653RecruitingPhase 2
T-cell therapy for stubborn Epstein-Barr virus after transplants
This trial tests an immune therapy made from EBV-targeted T-cells to treat EBV infections that do not improve with standard anti-viral medicines. It may help by strengthening the body’s ability to fight EBV after certain transplants or immune problems.
Los Angeles, CaliforniaAges 1 month–79 years - NCT03266640RecruitingPhase 2
CMV cell therapy for difficult-to-treat viral infection
This trial tests an immune cell treatment (CMV-specific cytotoxic T cells) for people with a CMV infection that is not improving despite standard antivirals, or who cannot tolerate them. If eligible, the treatment aims to help the body control the virus after transplant-related immune problems.
Los Angeles, CaliforniaAges 1 month–79 years - NCT03266627RecruitingPhase 2
Adenovirus T-cell therapy for hard-to-treat virus after transplants
This trial tests a special immune-cell treatment made to fight adenovirus in people whose adenovirus infection keeps coming back or won’t improve after transplant. It may help control infection when standard antiviral medicines are not working or can’t be tolerated.
Los Angeles, CaliforniaAges 1 month–79 years - NCT05385549RecruitingPhase 2
5-Year imatinib after GIST surgery for high-risk patients
This study looks at taking imatinib (a targeted anti-cancer pill) for 5 years after your GIST tumor has been fully removed. It is meant to lower the chance that GIST comes back in people considered “high risk.”
Seoul, SeoulAges 20 years+ - NCT05242393Recruiting
How daily body rhythms relate to recovery after stroke
This observational study looks at how your body’s daily rhythms may affect brain recovery after an ischemic stroke. It may help researchers understand what timing-related factors influence “neuroplasticity,” meaning the brain’s ability to adjust and heal.
Saint PetersburgAges 18–80 - NCT05247125RecruitingPhase 4
Testing light or melatonin to help brain recovery after stroke
This study looks at whether changing your sleep timing using light therapy or melatonin can improve “brain rewiring” after an ischemic stroke. It mainly focuses on people who arrive very soon after stroke symptoms and who also meet specific safety and sleep/medication requirements.
Saint PetersburgAges 18–80 - NCT05704166RecruitingPhase 2
Pirfenidone to prevent lung injury after breast radiation
This trial tests whether pirfenidone, a medication, can prevent acute lung injury caused by radiation therapy in people with breast cancer. You may be randomly assigned to pirfenidone or a placebo (inactive pill) to see which better protects the lungs during and after radiation.
Fuzhou, FujianAges 18–75 - NCT05925023Recruiting
Sirolimus for warm autoimmune hemolytic anemia after steroid failure
This trial studies sirolimus in adults with “warm” autoimmune hemolytic anemia (or Evans syndrome) when steroids have not worked or the anemia has returned. It may help control the immune attack on red blood cells, but there are specific safety checks for liver health and infections.
Beijing, Beijing MunicipalityAges 18–90 - NCT06697574Enrolling by invitation
Hypnotherapy for oral lichen planus
This trial tests whether hypnosis can help manage oral lichen planus (OLP), a chronic mouth condition. You will be randomly assigned to either hypnotherapy or a session explaining how your mind and immune system interact. Your symptoms will be checked after 2, 6, and 12 weeks.
Tel AvivAges 18 years+ - NCT06698458Recruiting
DaRT radiation plus chemo for advanced pancreatic cancer
This trial tests a new type of radiation called DaRT (Alpha DaRT) combined with standard chemotherapy for people with pancreatic cancer that is locally advanced or has spread. The goal is to see if adding this radiation treatment can help shrink tumors or slow the cancer's growth.
Gilbert, ArizonaAges 18–120 - NCT06699212RecruitingPhase 3
Light-activated therapy with immunotherapy for head and neck cancer
This trial tests a new light-activated treatment (ASP-1929) combined with an immunotherapy drug (pembrolizumab) as a first treatment for head and neck cancer that has come back in the same area but has not spread to other parts of the body. It aims to see if this combination works better than standard treatment alone.
Duarte, CaliforniaAges 18 years+ - NCT06702072Recruiting
Oxygen use after lung valve treatment
Researchers want to see if a bronchoscopic lung volume reduction procedure with Zephyr valves changes how much oxygen your body uses during simple tasks. You may be eligible if you are scheduled for this valve treatment and do not rely on constant oxygen for daily activities.
GroningenAges Any age - NCT06700187Recruiting
Does reducing sitting time improve thinking?
This study looks at whether taking short breaks from sitting can help your brain work better. You will visit a lab 4 times and will be asked to sit or take short breaks while your thinking is tested.
MaastrichtAges 18–35 - NCT06694714RecruitingPhase 4
Testing how long numbing medicine lasts on the nose
This study tests two different numbing medicines on the sides of the nose to see how long each lasts and which works better.
New York, New YorkAges 18 years+ - NCT06699615Enrolling by invitation
Assessing AI explanations by cancer doctors
This study asks lung cancer doctors at Penn Medicine to look at how an artificial intelligence tool explains its reasoning. The goal is to see if the explanations are clear and helpful for making treatment decisions.
Philadelphia, PennsylvaniaAges Any age - NCT06696235RecruitingPhase 4
Comparing fast vs standard kidney therapy for heart shock patients on ECMO
This trial tests whether starting kidney replacement therapy faster or at the usual time improves outcomes for people with severe heart failure (cardiogenic shock) who are on a heart-lung machine (ECMO) and develop sudden kidney injury.
SeoulAges 19 years+ - NCT06697327Enrolling by invitation
Testing a three-drug combo for newly diagnosed AML
This trial tests a combination of three drugs—daunorubicin, cytarabine, and venetoclax—for people with newly diagnosed AML who are strong enough to receive intensive chemotherapy. The goal is to see if adding venetoclax helps improve treatment outcomes.
Hefei, AnhuiAges 18–59 - NCT03991169RecruitingPhase 4
Oral iron for children with chronic kidney disease
This trial studies whether taking iron by mouth can improve iron levels and anemia (low red blood cell counts) in children with chronic kidney disease. It may help reduce fatigue and support normal blood-making, by comparing different approaches for children who meet specific iron test results.
New York, New YorkAges 1–21
Common questions
- Are there clinical trials studying Medication?
- Yes. Clin2 currently lists 7,138 recruiting studies that include Medication, drawn from the U.S. registry and rewritten for real people so you can see what each is testing and who it's for.
- How do I know if I qualify for a Medication trial?
- Each study lists its own eligibility criteria — rules about condition, age, and prior treatments. On every Clin2 trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Is Medication an approved treatment?
- A drug being studied in a trial may be investigational (still being tested) or already approved and being studied for a new use. Each study page explains what phase it's in. Clin2 does not provide medical advice — talk with your doctor about whether Medication or a specific trial is right for you.
Related treatments
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. A drug appearing here is being studied in a trial and may be investigational. Talk with your doctor about whether a specific treatment or trial is right for you.